Qualitative study of patients’ decisions to initiate injectable depot buprenorphine for opioid use disorder: the role of information and other factors

References

• Barnett, P. G., & Hui, S. S. (2000). The cost-effectiveness of methadone maintenance. The Mount Sinai Journal of Medicine, New York, 67(5-6), 365–374.
   PubMedGoogle Scholar
• Barnett, A., Savic, M., Lintzeris, N., Bathish, R., Arunogiri, S., Dunlop, A. J., Haber, P., Graham, R., Hayes, V., & Lubman, D. I. (2021). Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia. Drug and Alcohol Dependence, 227, 227, Article 108959. https://doi.org/10.1016/j.drugalcdep.2021.108959
   Web of Science ®Google Scholar
• Barnwal, P., Das, S., Mondal, S., Ramasamy, A., Maiti, T., & Saha, A. (2017). Probuphine® (buprenorphine implant): A promising candidate in opioid dependence. Therapeutic Advances in Psychopharmacology, 7(3), 119–134. https://doi.org/10.1177/2045125316681984
   PubMed Web of Science ®Google Scholar
• Bell, J. (2012). Opioid substitution treatment and its effectiveness: Review of the evidence. In J. Strang (Ed.), Medications in recovery: Re-orientating drug dependence treatment (Appendix C). National Treatment Agency.
   Google Scholar
• Brenna, I. H., Marciuch, A., Birkeland, B., Veseth, M., Rostad, B., Loberg, E. M., Solli, K. K., Tanum, L., & Weimand, B. (2022). ‘Not at all what I had expected’: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study. Journal of Substance Abuse Treatment, 136, 108667. https://doi.org/10.1016/j.jsat.2021.108667
   PubMed Web of Science ®Google Scholar
• Camurus (2018a). Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence. https://www.camurus.com/media/press-releases/2018/camurus-receives-eu-approval-for-weekly-and-monthly-buvidal-cam2038-for-opioid-dependence/
   Google Scholar
• Camurus (2018b). Buvidal® weekly and Buvidal® monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence. https://www.camurus.com/media/press-releases/2018/buvidal-weekly-and-buvidal-monthly-cam2038-approved-in-australia-as-the-first-long-acting-treatment-of-opioid-dependence/
   Google Scholar
• Dixon-Woods, M. (2001). Writing wrongs? An analysis of published discourses about the use of patient information leaflets. Social Science & Medicine, 52(9), 1417–1432. https://doi.org/10.1016/s0277-9536(00)00247-1
   PubMed Web of Science ®Google Scholar
• Dunlop, A. J., White, B., Roberts, J., Cretikos, M., Attalla, D., Ling, R., Searles, A., Mackson, J., Doyle, M. F., McEntyre, E., Attia, J., Oldmeadow, C., Howard, M. V., Murrell, T., Haber, P. S., & Lintzeris, N. (2022). Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings. Addiction, 117(2), 382–391. https://doi.org/10.1111/add.15627
   PubMed Web of Science ®Google Scholar
• Ecks, S. (2005). Pharmaceutical citizenship: Antidepressant marketing and the promise of demarginalization in India. Anthropology & Medicine, 12(3), 239–254. https://doi.org/10.1080/13648470500291360
   PubMedGoogle Scholar
• Graham, S., & Brookey, J. (2008). Do patients understand? The Permanente Journal, 3, 67–69.
   Google Scholar
• Haight, B. R., Learned, S. M., Laffont, C. M., Fudala, P. J., Zhao, Y., Garofalo, A. S., Greenwald, M. K., Nadipelli, V. R., Ling, W., Heidbreder, C., Andersen, J. L., Bailey, G. L., Bartley, S. R., Biunno, M. J., Boyett, B., Carr, J. M., Cifuentes, E., Duarte-Sckell, S. D., Dueno, O. R., … Wiest, K. L. (2019). Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 393(10173), 778–790. https://doi.org/10.1016/S0140-6736(18)32259-1
   PubMed Web of Science ®Google Scholar
• Hardey, M. (1999). Doctor in the house: The Internet as a source of lay health knowledge and the challenge of expertise. Sociology of Health & Illness, 21(6), 820–835. https://doi.org/10.1111/1467-9566.00185
   Web of Science ®Google Scholar
• Harris, J., & McElrath, K. (2012). Methadone as social control: Institutionalized stigma and the prospect of recovery. Qualitative Health Research, 22(6), 810–824. https://doi.org/10.1177/1049732311432718
   PubMed Web of Science ®Google Scholar
• Henwood, F., Wyatt, S., Hart, A., & Smith, J. (2003). ‘Ignorance is bliss sometimes’: Constraints on the emergence of the ‘informed patient’ in the changing landscapes of health information. Sociology of Health & Illness, 25(6), 589–607. https://doi.org/10.1111/1467-9566.00360
   PubMed Web of Science ®Google Scholar
• Indivior (2017). FDA approves SUBLOCADE™ (buprenorphine extended-release), the first and only once-monthly injectable buprenorphine formulation to treat moderate to severe opioid use disorder. Retrieved from http://www.indivior.com/investor-news/fda-approves-sublocade-buprenorphine-extendedrelease-first-monthly-injectable-buprenorphine-formulation-treat-moderate-severeopioid-use-disorder
   Google Scholar
• Itzoe, M., & Guarnieri, M. (2017). New developments in managing opioid addiction: Impact of a subdermal buprenorphine implant. Drug Design. Drug Design, Development and Therapy, 11, 1429–1437. https://doi.org/10.2147/DDDT.S109331
   PubMed Web of Science ®Google Scholar
• Johnson, B., Flensburg, O. L., & Capusan, A. J. (2022). Patient perspectives on depot buprenorphine treatment for opioid addiction: A qualitative interview study. Substance Abuse Treatment, Prevention, and Policy, 17(1), 40. https://doi.org/10.1186/s13011-022-00474-2
   PubMed Web of Science ®Google Scholar
• Lagios, K. (2021). Buprenorphine: Extended-release formulations “a game changer”! The Medical Journal of Australia, 214(11), 534–534.e1. https://doi.org/10.5694/mja2.51098
   PubMed Web of Science ®Google Scholar
• Laudet, A. B. (2007). What does recovery mean to you? Lessons from the recovery experience for research and practice. Journal of Substance Abuse Treatment, 33(3), 243–256. https://doi.org/10.1016/j.jsat.2007.04.014
   PubMed Web of Science ®Google Scholar
• Ling, W., Casadonte, P., Bigelow, G., Kampman, K. M., Patkar, A., Bailey, G. L., Rosenthal, R. N., & Beebe, K. L. (2010). Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. JAMA, 304(14), 1576–1583. https://doi.org/10.1001/jama.2010.1427
   PubMed Web of Science ®Google Scholar
• Lintzeris, N., Dunlop, A., & Masters, D. (2019). Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence. NSW Ministry of Health.
   Google Scholar
• Lofwall, M. R., Walsh, S. L., Nunes, E. V., Bailey, G. L., Sigmon, S. C., Kampman, K. M., Frost, M., Tiberg, F., Linden, M., Sheldon, B., Oosman, S., Peterson, S., Chen, M., & Kim, S. (2018). Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial. JAMA Internal Medicine, 178(6), 764–773. https://doi.org/10.1001/jamainternmed.2018.1052
   PubMed Web of Science ®Google Scholar
• Madden, A., Hopwood, M., Neale, J., & Treloar, C. (2018). Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PloS One, 13(11)Article, e0207226. https://doi.org/10.1371/journal.pone.0207226
   PubMed Web of Science ®Google Scholar
• Mariani, J. J., Mahony, A. L., Podell, S. C., Brooks, D. J., Brezing, C., Luo, S. X., Naqvi, N. H., & Levin, F. R. (2021). Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanyl. The American Journal on Addictions, 30(5), 470–476. https://doi.org/10.1111/ajad.13193
   PubMed Web of Science ®Google Scholar
• Matheson, C., Foster, R., Schofield, J., & Browne, T. (2022). Long-acting depot buprenorphine in people who are homeless: Views and experiences. Journal of Substance Abuse Treatment, 139, 139, Article 108781. https://doi.org/10.1016/j.jsat.2022.108781
   Web of Science ®Google Scholar
• Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2, CD002207.
   PubMed Web of Science ®Google Scholar
• McElrath, K. (2018). Medication-assisted treatment for opioid addiction in the United States: Critique and commentary. Substance Use & Misuse, 53(2), 334–343. https://doi.org/10.1080/10826084.2017.1342662
   PubMed Web of Science ®Google Scholar
• McKinlay, J. B., & Marceau, L. D. (2002). The end of golden age of doctoring. International Journal of Health Services : planning, Administration, Evaluation, 32(2), 379–416. https://doi.org/10.2190/JL1D-21BG-PK2N-J0KD
   PubMed Web of Science ®Google Scholar
• Neale, J. (1998). Drug users’ views of prescribed methadone. Drugs: Education, Prevention and Policy, 5, 33–45. https://doi.org/10.3109/09687639809035769
   Web of Science ®Google Scholar
• Neale, J. (2016). Iterative categorisation (IC): A systematic technique for analysing qualitative data. Addiction, 111(6), 1096–1106. https://doi.org/10.1111/add.13314
   PubMed Web of Science ®Google Scholar
• Neale, J. (2021). Iterative Categorisation (part 2): Interpreting qualitative data. Addiction, 116(3), 668–676. https://doi.org/10.1111/add.15259
   PubMed Web of Science ®Google Scholar
• Neale, J., Panebianco, D., Finch, E., Marsden, J., Mitcheson, L., Rose, D., Wykes, T., & Strang, J. (2016). Emerging consensus on measuring addiction recovery: Findings from a multi-stakeholder consultation exercise. Drugs: Education, Prevention and Policy, 23, 31–40. https://doi.org/10.3109/09687637.2015.1100587
   Web of Science ®Google Scholar
• Neale, J., Tompkins, C., McDonald, R., & Strang, J. (2018). Patient views of opioid pharmacotherapy bio-delivery systems: Qualitative study to assist treatment decision making. Experimental and Clinical Psychopharmacology, 26(6), 570–581. https://doi.org/10.1037/pha0000217
   PubMed Web of Science ®Google Scholar
• Neale, J., Tompkins, C., & Strang, J. (2019a). Prolonged-release opioid agonist therapy: Qualitative study exploring patients’ views of one-week, one-month and six-month buprenorphine formulations. Harm Reduction Journal, 16(1), 25. https://doi.org/10.1186/s12954-019-0296-4
   PubMedGoogle Scholar
• Neale, J., Tompkins, C., & Strang, J. (2019b). Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences. Drug and Alcohol Review, 38(5), 510–518. https://doi.org/10.1111/dar.12939
   PubMed Web of Science ®Google Scholar
• Nielsen, S., Larance, B., Degenhardt, L., Gowing, L., Kehler, C., & Lintzeris, N. (2016). Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database of Systematic Reviews, 5, CD011117.
   Google Scholar
• Peterson, M. (2009). An introduction to decision theory. Cambridge University Press.
   Google Scholar
• Rance, J., Rhodes, T., & Lancaster, K. (2021). Pharmaceutical citizenship in an era of universal access to hepatitis C treatment: Situated potentials and limits. Health, 28, 1363459320988887.
   Google Scholar
• Rooks, R. N., Wiltshire, J. C., Elder, K., BeLue, R., & Gary, L. C. (2012). Health information seeking and use outside of the medical encounter: Is it associated with race and ethnicity? Social Science & Medicine (1982), 74(2), 176–184. https://doi.org/10.1016/j.socscimed.2011.09.040
   PubMed Web of Science ®Google Scholar
• SAMHSA (2018). Medication-assisted treatment. https://www.samhsa.gov/medication-assisted-treatment
   Google Scholar
• Saunders, E. C., Moore, S. K., Walsh, O., Metcalf, S. A., Budney, A. J., Scherer, E., & Marsch, L. A. (2020). Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders. Journal of Substance Abuse Treatment, 111, 54–66. https://doi.org/10.1016/j.jsat.2020.01.009
   PubMed Web of Science ®Google Scholar
• Stotts, A. L., Dodrill, C. L., & Kosten, T. R. (2009). Opioid dependence treatment: Options in pharmacotherapy. Expert Opinion on Pharmacotherapy, 10(11), 1727–1740. https://doi.org/10.1517/14656560903037168
   PubMed Web of Science ®Google Scholar
• Tompkins, C., Neale, J., & Strang, J. (2019). Opioid users’ willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. Journal of Substance Abuse Treatment, 104, 64–71. https://doi.org/10.1016/j.jsat.2019.06.007
   PubMed Web of Science ®Google Scholar
• Treloar, C., Lancaster, K., Gendera, S., Rhodes, T., Shahbazi, J., Byrne, M., Degenhardt, L., & Farrell, M. (2022). Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot. The International Journal on Drug Policy, 107, 107, Article 103788. https://doi.org/10.1016/j.drugpo.2022.103788
   Web of Science ®Google Scholar
• VERBI Software (2017). MAXQDA computer programme. VERBI.
   Google Scholar
• Walsh, S. L., & Eissenberg, T. (2003). The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic. Drug and Alcohol Dependence, 70(2), S13–S27. https://doi.org/10.1016/S0376-8716(03)00056-5
   PubMedGoogle Scholar